BioSpace News Archive

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a targeted oncology company, will announce financial results for the fourth quarter and full year of 2022 along with recent corporate updates on February 28, 2023.

Acorda Therapeutics, Inc. announced that the Nasdaq Hearings Panel has granted the Company’s extension request until June 20, 2023 to regain compliance with the Nasdaq’s minimum $1 bid price per share requirement.

Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, announced results for the third quarter of fiscal year 2023 ended December 31, 2022 (“Third Quarter”).

The Cure Brain Cancer Foundation CEO has announced he will be making the harrowing trek to the South Pole in order to raise awareness and funds for cancer research.

During festivities at the Glaucoma Research Foundation Annual Gala at the Westin St. Francis last week, president and CEO Thomas M. Brunner awarded the 2023 Shaffer Prize for Innovative Glaucoma Research to both Rachel Wang Kuchtey, MD, PhD of Vanderbilt University and Lev Prasov, MD, PhD from the Kellogg Eye Institute, University of Michigan.

Cutera, Inc., a leading provider of aesthetic and dermatology solutions, announced that it will report financial results for the fourth quarter and full year of 2022 after the market close on Tuesday, February 28, 2023.

Sonendo, Inc., a leading dental technology company and developer of the GentleWave® System, announced the results of its latest survey, which revealed high consumer interest levels in its innovative technology.

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today published on the successful discovery of alpaca-derived VHH antibodies using a disruptive, function-forward in vivo discovery workflow developed by Abveris, also known as Twist Boston, on the Beacon optofluidic platform.

Sesen Bio, Inc. and Carisma Therapeutics Inc. announced that the companies have reached a voting and support agreement with Bradley L. Radoff and Michael Torok.

Aditxt, Inc. announces the formation of a U.S.-based wholly- owned subsidiary, Pearsanta, Inc., to accelerate the growth of Aditxt’s second program, AditxtScore™, through future strategic revenue and growth-oriented transactions.